Veliparib monotherapy to patients with BRCA germ line mutation and platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer: A phase I/II study
International Journal of Gynecological Cancer Nov 08, 2017
Steffensen KD, et al. - This study was planned to assess the effect of veliparib in patients with known BRCA1/2 mutations and with a platinum-resistant or intermediate sensitive relapse of ovarian cancer (OC). As per observations, in heavily pretreated patients with relapse of OC, treatment with veliparib had a considerable efficacy with an acceptable toxicity profile.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
